Literature DB >> 22732677

The demographic and medical correlates of plasma aβ40 and aβ42.

Andrea L Metti1, Jane A Cauley, Hilsa N Ayonayon, Tamara B Harris, Caterina Rosano, Jeff D Williamson, Kristine Yaffe.   

Abstract

Plasma amyloid β-42 (Aβ42) and Aβ42/Aβ40 are increasingly recognized as biomarkers for dementia, with low levels indicating increased risk. Little is known about the demographic and medical correlates of plasma Aβ40 or Aβ42. In 997 community-dwelling, nondemented older adults from the Health, Aging, and Body Composition Study, we determined the cross-sectional association between a wide range of demographic and medical variables with Aβ40 and Aβ42. In multivariate stepwise linear regression models, Aβ40 was significantly associated with race (β=-14.70, F=22.01, P<0.0001), age (β=1.34, F=6.39, P=0.01), creatinine (β=52.91, F=151.77, P<0.0001), and the serum brain-derived neurotrophic factor (β=-0.0004, F=7.34, P=0.007); Aβ42 was significantly associated with race (β=-3.72, F=30.83, P<0.0001), sex (β=1.39, F=4.32, P=0.04), education (β=1.50, F=4.78, P=0.03), apolipoprotein E e4 genotype (β=-2.82, F=16.57, P<0.0001), and creatinine (β=9.32, F=120.09, P<0.0001). These correlates should be considered as potential confounders in future studies investigating plasma Aβ as a biomarker of dementia. Understanding fully how these correlates mediate or modify the association between plasma Aβ and dementia will be a fundamental step in determining the biological pathways through which plasma Aβ40 and Aβ42 are associated with dementia, and in determining their full potential as biomarkers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22732677      PMCID: PMC3473156          DOI: 10.1097/WAD.0b013e318260a8cb

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  32 in total

1.  Risk of dementia among white and African American relatives of patients with Alzheimer disease.

Authors:  Robert C Green; L Adrienne Cupples; Rodney Go; Kelly S Benke; Timi Edeki; Patrick A Griffith; Mary Williams; Yvonne Hipps; Neill Graff-Radford; David Bachman; Lindsay A Farrer
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  The Modified Mini-Mental State (3MS) examination.

Authors:  E L Teng; H C Chui
Journal:  J Clin Psychiatry       Date:  1987-08       Impact factor: 4.384

4.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

5.  Insulin acts intracellularly on proteasomes through insulin-degrading enzyme.

Authors:  W C Duckworth; R G Bennett; F G Hamel
Journal:  Biochem Biophys Res Commun       Date:  1998-03-17       Impact factor: 3.575

6.  Inflammatory markers and cognition in well-functioning African-American and white elders.

Authors:  K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

7.  Rapid estimate of adult literacy in medicine: a shortened screening instrument.

Authors:  T C Davis; S W Long; R H Jackson; E J Mayeaux; R B George; P W Murphy; M A Crouch
Journal:  Fam Med       Date:  1993-06       Impact factor: 1.756

8.  The relationship between literacy and glycemic control in a diabetes disease-management program.

Authors:  Russell Rothman; Robb Malone; Betsy Bryant; Cheryl Horlen; Darren DeWalt; Michael Pignone
Journal:  Diabetes Educ       Date:  2004 Mar-Apr       Impact factor: 2.140

9.  Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample.

Authors:  G Jarvik; E B Larson; K Goddard; G D Schellenberg; E M Wijsman
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

10.  The association between physical function and lifestyle activity and exercise in the health, aging and body composition study.

Authors:  Jennifer S Brach; Eleanor M Simonsick; Stephen Kritchevsky; Kristine Yaffe; Anne B Newman
Journal:  J Am Geriatr Soc       Date:  2004-04       Impact factor: 5.562

View more
  12 in total

1.  Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer's Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial.

Authors:  Kim E Innes; Terry Kit Selfe; Kathleen Brundage; Caitlin Montgomery; Sijin Wen; Sahiti Kandati; Hannah Bowles; Dharma Singh Khalsa; Zenzi Huysmans
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

2.  Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia.

Authors:  Pariya L Fazeli; David J Moore; Donald R Franklin; Anya Umlauf; Robert K Heaton; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned C Sacktor; Susan Morgello; David M Simpson; John A McCutchan; Igor Grant; Scott L Letendre
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

3.  Age and its association with low insulin and high amyloid-β peptides in blood.

Authors:  Huajie Li; Haihao Zhu; Max Wallack; Mkaya Mwamburi; Samer O Abdul-Hay; Malcolm A Leissring; Wei Qiao Qiu
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

4.  Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.

Authors:  Agustín Ruiz; Pedro Pesini; Ana Espinosa; Virginia Pérez-Grijalba; Sergi Valero; Oscar Sotolongo-Grau; Montserrat Alegret; Inmaculada Monleón; Asunción Lafuente; Mar Buendía; Marta Ibarria; Susana Ruiz; Isabel Hernández; Itziar San José; Lluís Tárraga; Mercè Boada; Manuel Sarasa
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

5.  Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer's disease.

Authors:  Jung-Lung Hsu; Wei-Ju Lee; Yi-Chu Liao; Jiing-Feng Lirng; Shuu-Jiun Wang; Jong-Ling Fuh
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

6.  Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.

Authors:  Lih-Fen Lue; Marwan N Sabbagh; Ming-Jang Chiu; Naomi Jing; Noelle L Snyder; Christopher Schmitz; Andre Guerra; Christine M Belden; Ta-Fu Chen; Che-Chuan Yang; Shieh-Yueh Yang; Douglas G Walker; Kewei Chen; Eric M Reiman
Journal:  Front Aging Neurosci       Date:  2017-07-24       Impact factor: 5.750

7.  The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers.

Authors:  Ho Sik Shin; Seung-Keun Lee; Saeromi Kim; Hyung-Jun Kim; Won Seok Chae; Sun Ah Park
Journal:  Dement Neurocogn Disord       Date:  2016-12-31

Review 8.  Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker.

Authors:  Jon B Toledo; Leslie M Shaw; John Q Trojanowski
Journal:  Alzheimers Res Ther       Date:  2013-03-08       Impact factor: 6.982

9.  Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume.

Authors:  Oscar Sotolongo-Grau; Pedro Pesini; Sergi Valero; Asunción Lafuente; Mar Buendía; Virginia Pérez-Grijalba; Itziar San José; Marta Ibarria; Miguel A Tejero; Joan Giménez; Isabel Hernández; Lluís Tárraga; Agustín Ruiz; Mercé Boada; Manuel Sarasa
Journal:  Alzheimers Res Ther       Date:  2014-10-20       Impact factor: 6.982

10.  The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.

Authors:  Jung-Lung Hsu; Wei-Ju Lee; Yi-Chu Liao; Shuu-Jiun Wang; Jong-Ling Fuh
Journal:  Alzheimers Res Ther       Date:  2017-11-23       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.